Mackay, H J

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia. [electronic resource] - Gynecologic oncology Apr 2012 - 136-40 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural

1095-6859

10.1016/j.ygyno.2011.11.042 doi


Adult
Aged
Antineoplastic Agents--adverse effects
California
Carcinosarcoma--drug therapy
Chicago
Disease-Free Survival
Drug Administration Schedule
Female
Genital Neoplasms, Female--drug therapy
Humans
Kaplan-Meier Estimate
Leiomyosarcoma--drug therapy
Middle Aged
Receptors, Vascular Endothelial Growth Factor
Recombinant Fusion Proteins--adverse effects
Treatment Outcome